Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03302247

Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

Non Small Cell Lung Cancer Stage IIIB Clinical Trial

Official title:
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

Clinical Trial Summary

Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using recently approved immunotherapy with antibody, Nivolumab. Both the therapies have limitation due to development of tolerance or immunosuppression. This trial combines one drug from each category, immunotherapeutic Nivolumab and chemotherapeutic gemcitabine as it was reported that gemcitabine reduces immunosuppression by killing myeloid derived suppressor cells, thereby increasing the efficacy of Nivolumab.

Clinical Trial Description

Primary Objective • The primary objective of this proposal is to evaluate gemcitabine as a method of MDSC depletion. Secondary Objectives - Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number. - Determine the tolerability and clinical activity (including response rate and survival) of this approach. - Correlate MDSC number with tumor PD-L1 expression ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03302247
Study type Interventional
Source Fox Chase Cancer Center
Contact
Status Terminated
Phase Phase 2
Start date January 15, 2018
Completion date July 12, 2019
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03288870 - Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) Phase 2/Phase 3
Completed NCT03304093 - Immunotherapy by Nivolumab for HIV+ Patients Phase 2
Active, not recruiting NCT03307785 - Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 Phase 1
Active, not recruiting NCT04432207 - A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03396185 - Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT06436144 - Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC Phase 2
Completed NCT03472053 - A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer Phase 2
Active, not recruiting NCT03334071 - Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients N/A